Physician profile
Phillip E Maxwell
NPI 1891120127
$10,273.15
in general payments reported to CMS, 2019-2025
17 companies · $3,627 in 2025
The $3,627 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $499 · 2023: $2,149 · 2024: $3,613 · 2025: $3,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,389.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,025.30 | 2022-2025 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $3,506.02 | 2022-2025 | Biktarvy, Yeztugo, Descovy |
| Merck Sharp & Dohme LLC | $781.44 | 2022-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Theratechnologies INC. | $570.95 | 2022-2025 | Trogarzo, Egrifta |
| Janssen Pharmaceuticals, INC | $308.21 | 2021-2022 | |
| Janssen Biotech, INC. | $250.99 | 2022-2023 | Symtuza |
| Emd Serono, INC. | $166.39 | 2022-2025 | Serostim |
| Glaxosmithkline, LLC. | $156.23 | 2023 | Arexvy, Shingrix |
| Napo Pharmaceuticals INC | $116.37 | 2023-2025 | Mytesi |
| Abbvie INC. | $103.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $92.23 | 2021 | |
| Grifols USA, LLC | $66.91 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.17 | 2023-2024 | Xifaxan |
| Tolmar, INC. | $23.06 | 2025 | Jatenzo |
| Lilly USA, LLC | $17.26 | 2025 | Zepbound |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $16.56 | 2023 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $15.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.